

Ubaldo Bonuccelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/583202/publications.pdf>

Version: 2024-02-01

362
papers

16,699
citations

19657

61
h-index

24258

110
g-index

371
all docs

371
docs citations

371
times ranked

19496
citing authors

#	ARTICLE	IF	CITATIONS
1	Bipolar Spectrum disorders in Parkinson's disease: a systematic evaluation. CNS Spectrums, 2022, 27, 355-361.	1.2	6
2	What Does the Brain Have to Keep Working at Its Best? Resilience Mechanisms Such as Antioxidants and Brain/Cognitive Reserve for Counteracting Alzheimer's Disease Degeneration. Biology, 2022, 11, 650.	2.8	9
3	Is DAT imaging abnormality in normal pressure hydrocephalus always suggestive of degeneration?. Neurological Sciences, 2021, 42, 723-726.	1.9	5
4	Locus Coeruleus Magnetic Resonance Imaging in Neurological Diseases. Current Neurology and Neuroscience Reports, 2021, 21, 2.	4.2	27
5	Prevalence and impact of COVID-19 in Parkinson's disease: evidence from a multi-center survey in Tuscany region. Journal of Neurology, 2021, 268, 1179-1187.	3.6	70
6	Connected speech in progressive supranuclear palsy: a possible role in differential diagnosis. Neurological Sciences, 2021, 42, 1483-1490.	1.9	3
7	Effects of combined training on neuropsychiatric symptoms and quality of life in patients with cognitive decline. Aging Clinical and Experimental Research, 2021, 33, 1249-1257.	2.9	15
8	Longitudinal changes in MoCA performances in patients with mild cognitive impairment and small vessel disease. Results from the VMCI-Tuscany Study. Cerebral Circulation - Cognition and Behavior, 2021, 2, 100008.	0.9	1
9	Apolipoprotein E Polymorphism and Oxidative Stress in Human Peripheral Blood Cells: Can Physical Activity Reactivate the Proteasome System through Epigenetic Mechanisms?. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-16.	4.0	11
10	Mild Cognitive Impairment in de novo Parkinson's Disease: Selective Attention Deficit as Early Sign of Neurocognitive Decay. Frontiers in Psychology, 2021, 12, 546476.	2.1	2
11	Î±-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients. Journal of Alzheimer's Disease, 2021, 80, 885-893.	2.6	9
12	Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson's Disease. Journal of Clinical Medicine, 2021, 10, 2302.	2.4	8
13	P2X7 receptor/NLRP3 inflammasome complex and Î±-synuclein in peripheral blood mononuclear cells: a prospective study in newly-diagnosed, treatment-naïve Parkinson's disease. European Journal of Neurology, 2021, 28, 2648-2656.	3.3	12
14	Dissecting the Interplay Between Time of Dementia and Cognitive Profiles in Lewy Body Dementias. Journal of Alzheimer's Disease, 2021, 84, 757-766.	2.6	1
15	Locus Coeruleus magnetic resonance imaging in cognitively intact elderly subjects. Brain Imaging and Behavior, 2021, , 1.	2.1	8
16	Transcranial Direct Current Stimulation (tDCS) as a Useful Rehabilitation Strategy to Improve Cognition in Patients With Alzheimer's Disease and Parkinson's Disease: An Updated Systematic Review of Randomized Controlled Trials. Frontiers in Neurology, 2021, 12, 798191.	2.4	13
17	Excessive daytime sleepiness and fatigue in neurological disorders. Sleep and Breathing, 2020, 24, 413-424.	1.7	41
18	Multicenter Study on Sleep and Circadian Alterations as Objective Markers of Mild Cognitive Impairment and Alzheimer's Disease Reveals Sex Differences. Journal of Alzheimer's Disease, 2020, 78, 1707-1719.	2.6	20

#	ARTICLE	IF	CITATIONS
19	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020, 57, 4667-4691.	4.0	33
20	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. <i>Neurology</i> , 2020, 95, e2854-e2865.	1.1	25
21	Red blood cell α -synuclein heteroaggregates can discriminate healthy controls from cognitively impaired subjects of the AD-LBD spectrum. <i>Alzheimer's and Dementia</i> , 2020, 16, e040618.	0.8	0
22	Sex differences in red blood cell α -synuclein protein and its heteroaggregates with amyloid β and tau in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042079.	0.8	0
23	Assessment of the integrity of the noradrenergic nucleus locus coeruleus during normal ageing by neuromelanin β T MRI. <i>Alzheimer's and Dementia</i> , 2020, 16, e043332.	0.8	0
24	In vivo assessment of the noradrenergic nucleus locus coeruleus in Alzheimer's disease and other types of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e043616.	0.8	0
25	Aerobic Exercise and Healthy Nutrition as Neuroprotective Agents for Brain Health in Patients with Parkinson's Disease: A Critical Review of the Literature. <i>Antioxidants</i> , 2020, 9, 380.	5.1	9
26	Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single-Photon Emission Computed Tomography Study. <i>Movement Disorders</i> , 2020, 35, 1028-1036.	3.9	17
27	Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α -synucleinopathies. <i>Journal of Neurology</i> , 2020, 267, 3444-3456.	3.6	17
28	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 421-441.	3.1	42
29	Theory of mind in Parkinson's disease: evidences in drug-naïve patients and longitudinal effects of dopaminergic therapy. <i>Neurological Sciences</i> , 2020, 41, 2761-2766.	1.9	4
30	Non-pharmacological interventions for Parkinson's disease mild cognitive impairment: future directions for research. <i>Neural Regeneration Research</i> , 2020, 15, 1650.	3.0	11
31	Risk factors for impulse control disorders and related behaviors in Parkinson's disease: secondary analyses of the ICARUS study. <i>Journal of Drug Assessment</i> , 2019, 8, 159-166.	2.2	8
32	Impact of ApoE Polymorphism and Physical Activity on Plasma Antioxidant Capability and Erythrocyte Membranes. <i>Antioxidants</i> , 2019, 8, 538.	5.1	11
33	Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine. <i>Toxins</i> , 2019, 11, 608.	3.4	18
34	Quantitative susceptibility mapping in atypical Parkinsonisms. <i>NeuroImage: Clinical</i> , 2019, 24, 101999.	2.7	49
35	Clinical Correlates of Cerebral Amyloid Deposition in Parkinson's Disease Dementia: Evidence from a PET Study. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 597-609.	2.6	13
36	Insomnia and hot flashes. <i>Maturitas</i> , 2019, 126, 51-54.	2.4	23

#	ARTICLE	IF	CITATIONS
37	Freezing of gait and dementia in parkinsonism: A retrospective caseâ€“control study. Brain and Behavior, 2019, 9, e01247.	2.2	8
38	Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome. Brain and Behavior, 2019, 9, e01182.	2.2	5
39	Potential Diagnostic Value of Red Blood Cells $\hat{\pm}$ -Synuclein Heteroaggregates in Alzheimerâ€™s Disease. Molecular Neurobiology, 2019, 56, 6451-6459.	4.0	24
40	A longitudinal study of polysomnographic variables in patients with mild cognitive impairment converting to Alzheimer's disease. Journal of Sleep Research, 2019, 28, e12821.	3.2	29
41	Social cognition in idiopathic generalized epilepsies and potential neuroanatomical correlates. Epilepsy and Behavior, 2019, 100, 106118.	1.7	14
42	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates \hat{A}^2 , tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
43	Disruption of sleep-wake continuum in myotonic dystrophy type 1: Beyond conventional sleep staging. Neuromuscular Disorders, 2018, 28, 414-421.	0.6	14
44	Application of the DSM-5 Criteria for Major Neurocognitive Disorder to Vascular MCI Patients. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 104-116.	1.3	13
45	Vascular Function Is Improved After an Environmental Enrichment Program. Hypertension, 2018, 71, 1218-1225.	2.7	18
46	Present and Future of Ultra-High Field MRI in Neurodegenerative Disorders. Current Neurology and Neuroscience Reports, 2018, 18, 31.	4.2	10
47	$\hat{\pm}$ -Synuclein Aggregates with \hat{I}^2 -Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects. Molecular Neurobiology, 2018, 55, 2653-2675.	4.0	32
48	Oxidative Stress Assessment in Alzheimerâ€™s Disease: A Clinic Setting Study. American Journal of Alzheimer's Disease and Other Dementias, 2018, 33, 35-41.	1.9	15
49	The Precuneus â€“ A Witness for Excessive \hat{A}^2 Gathering in Alzheimerâ€™s Disease Pathology. Neurodegenerative Diseases, 2018, 18, 302-309.	1.4	13
50	Functional magnetic resonance imaging with encoding task in patients with mild cognitive impairment and different severity of leukoaraiosis. Psychiatry Research - Neuroimaging, 2018, 282, 126-131.	1.8	5
51	Advances in the pharmacotherapeutic management of dementia with Lewy bodies. Expert Opinion on Pharmacotherapy, 2018, 19, 1643-1653.	1.8	9
52	$\hat{\pm}$ -Synuclein Aggregated with Tau and \hat{I}^2 -Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise. Frontiers in Aging Neuroscience, 2018, 10, 17.	3.4	18
53	$\hat{\pm}$ -Synuclein Heterocomplexes with \hat{I}^2 -Amyloid Are Increased in Red Blood Cells of Parkinsonâ€™s Disease Patients and Correlate with Disease Severity. Frontiers in Molecular Neuroscience, 2018, 11, 53.	2.9	51
54	Thyroid hormone levels in the cerebrospinal fluid correlate with disease severity in euthyroid patients with Alzheimerâ€™s disease. Endocrine, 2017, 55, 981-984.	2.3	21

#	ARTICLE	IF	CITATIONS
55	Methylation analysis of DNA repair genes in Alzheimer's disease. Mechanisms of Ageing and Development, 2017, 161, 105-111.	4.6	16
56	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. Expert Review of Proteomics, 2017, 14, 285-299.	3.0	78
57	Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 993-1003.	0.8	39
58	Olfactory evaluation in Mild Cognitive Impairment: correlation with neurocognitive performance and endothelial function. European Journal of Neuroscience, 2017, 45, 1279-1288.	2.6	20
59	Detecting cognitive impairment at the early stages: The challenge of first line assessment. Journal of the Neurological Sciences, 2017, 377, 12-18.	0.6	9
60	ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 317-324.	1.9	119
61	A single center study: A β 242/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting. Neurological Sciences, 2017, 38, 1791-1797.	1.9	16
62	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
63	Cyclic alternating pattern and interictal epileptiform discharges during morning sleep after sleep deprivation in temporal lobe epilepsy. Epilepsy and Behavior, 2017, 73, 131-136.	1.7	13
64	Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder. Parkinsonism and Related Disorders, 2017, 43, 105-109.	2.2	23
65	Treatment of epilepsy in patients with Alzheimer's disease. Expert Review of Neurotherapeutics, 2017, 17, 309-318.	2.8	20
66	The Neuroanatomy of the Reticular Nucleus Locus Coeruleus in Alzheimer's Disease. Frontiers in Neuroanatomy, 2017, 11, 80.	1.7	44
67	Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition. Parkinsonism and Related Disorders, 2016, 27, 81-84.	2.2	24
68	Biomarker-guided classification scheme of neurodegenerative diseases. Journal of Sport and Health Science, 2016, 5, 383-387.	6.5	22
69	Acute encephalopathy of the temporal lobes leading to m.3243A > G. When MELAS is not always MELAS. Mitochondrion, 2016, 30, 148-150.	3.4	3
70	Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1. Neurolmage: Clinical, 2016, 12, 190-197.	2.7	51
71	Social cognition in Juvenile Myoclonic Epilepsy. Epilepsy Research, 2016, 128, 61-67.	1.6	30
72	D β -Oxytocin plasma levels as predictor of social cognition in huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A35.2-A35.	1.9	0

#	ARTICLE	IF	CITATIONS
73	F5â€¦Social cognition in huntingtonâ€™s disease: evidence from a prospective study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A50.1-A50.	1.9	0
74	A review of adverse events linked to dopamine agonists in the treatment of Parkinsonâ€™s disease. Expert Opinion on Drug Safety, 2016, 15, 181-198.	2.4	30
75	Nigral involvement in atypical parkinsonisms: evidence from a pilot study with ultra-high field MRI. Journal of Neural Transmission, 2016, 123, 509-513.	2.8	16
76	Chronic Migraine With Medication Overuse and OnabotulinumtoxinA: Two Positive Case Reports of a Modified Injection Protocol. Headache, 2016, 56, 402-403.	3.9	1
77	Epilepsy occurrence in patients with Alzheimerâ€™s disease: clinical experience in a tertiary dementia center. Neurological Sciences, 2016, 37, 645-647.	1.9	15
78	Operationalizing mild cognitive impairment criteria in small vessel disease: the VMCI-Tuscany Study. , 2016, 12, 407-418.		34
79	Association study between the DNMT3A -448A>G polymorphism and risk of Alzheimer's disease in Caucasians of Italian origin. American Journal of Neurodegenerative Disease, 2016, 5, 85-93.	0.1	3
80	Cerebral sinus venous thrombosis. Blood Coagulation and Fibrinolysis, 2015, 26, 505-508.	1.0	9
81	Evidences of Reduced Antioxidant Activity in Patients With Chronic Migraine and Medicationâ€™Overuse Headache. Headache, 2015, 55, 984-991.	3.9	13
82	P058. Refractory chronic migraine, fatigue and OnabotulinumtoxinA: a clinic setting experience. Journal of Headache and Pain, 2015, 16, A113.	6.0	1
83	P041. Analysis of body mass index, psychiatric comorbidity, sleep-wake pattern and occurrence of fatigue in episodic and chronic migraine patients. Journal of Headache and Pain, 2015, 16, A188.	6.0	1
84	Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report. Movement Disorders, 2015, 30, 1148-1149.	3.9	18
85	Alzheimerâ€™s Pathogenesis and Its Link to the Mitochondrion. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-8.	4.0	28
86	Relation between plasmatic and cerebrospinal fluid oxidative stress biomarkers and intrathecal Ig synthesis in Multiple Sclerosis patients. Journal of Neuroimmunology, 2015, 283, 39-42.	2.3	9
87	Genetics of ischaemic stroke in young adults. BBA Clinical, 2015, 3, 96-106.	4.1	27
88	Morphometric and functional MRI changes in essential tremor with and without resting tremor. Journal of Neurology, 2015, 262, 719-728.	3.6	39
89	Non-rapid eye movement sleep instability in mild cognitive impairment: a pilot study. Sleep Medicine, 2015, 16, 1139-1145.	1.6	65
90	â€œCardioembolic Profileâ€•in Patients with Ischemic Stroke: Data from the Analysis of 1037 Cases. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1287-1290.	1.6	3

#	ARTICLE	IF	CITATIONS
91	Apomorphine hydrochloride for the treatment of Parkinson's disease. Expert Review of Neurotherapeutics, 2015, 15, 723-732.	2.8	21
92	Mediterranean spotted fever: an unusual clinical and neuroradiological presentation. Neurological Sciences, 2015, 36, 2141-2143.	1.9	2
93	Methylation analysis of multiple genes in blood DNA of Alzheimer's disease and healthy individuals. Neuroscience Letters, 2015, 600, 143-147.	2.1	63
94	RE response to: "Entacapone, Parkinson's disease, "functional adrenergic denervation", and Takotsubo syndrome", Parkinsonism and Related Disorders, 2015, 21, 427.	2.2	2
95	Reliability of administrative data for the identification of Parkinson's disease cohorts. Neurological Sciences, 2015, 36, 783-786.	1.9	23
96	Mesolimbic dopaminergic dysfunction in Parkinson's disease depression: evidence from a 123I-FP-CIT SPECT investigation. Journal of Neural Transmission, 2015, 122, 1143-1147.	2.8	23
97	Comparison of 3T and 7T Susceptibility-Weighted Angiography of the Substantia Nigra in Diagnosing Parkinson Disease. American Journal of Neuroradiology, 2015, 36, 461-466.	2.4	80
98	A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. European Journal of Neurology, 2015, 22, 1184-1191.	3.3	75
99	Imaging in Glucocerebrosidase-Associated Parkinsonism: Current Status and Implications for Pathophysiology. Neurodegenerative Diseases, 2015, 15, 271-280.	1.4	3
100	Clinical features associated with ictal osmophobia in migraine. Neurological Sciences, 2015, 36, 43-46.	1.9	26
101	A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2015, 278, 53-59.	2.3	25
102	Plasmatic oxidative stress biomarkers in multiple sclerosis: Relation with clinical and demographic characteristics. Clinical Biochemistry, 2015, 48, 19-23.	1.9	34
103	Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease. Acta Neurologica Scandinavica, 2015, 131, 191-195.	2.1	26
104	Preferential occurrence of attacks during night sleep and/or upon awakening negatively affects migraine clinical presentation. Functional Neurology, 2015, 30, 119-23.	1.3	13
105	Current treatment and future prospects of dopa-induced dyskinesias. Drugs of Today, 2015, 51, 315.	1.1	14
106	NREM sleep transient events in fronto-temporal dementia: beyond sleep stage architecture. Archives Italiennes De Biologie, 2015, 153, 214-24.	0.4	5
107	A Pilot Study Evaluating the Contribution of SLC19A1(RFC-1) 80G>A Polymorphism to Alzheimer's Disease in Italian Caucasians. BioMed Research International, 2014, 2014, 1-6.	1.9	1
108	Mild Depressive Symptoms are Associated With Enhanced Affective Theory of Mind in Nonclinical Adult Women. Journal of Neuropsychiatry and Clinical Neurosciences, 2014, 26, E63-E64.	1.8	7

#	ARTICLE	IF	CITATIONS
109	Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Movement Disorders, 2014, 29, 229-237.	3.9	239
110	Abnormal response to photic stimulation in Juvenile Myoclonic Epilepsy: An EEG-MRI study. Epilepsia, 2014, 55, 1038-1047.	5.1	47
111	Dopamine Agonist Modifies Cortical Activity in Parkinson Disease. Clinical Neuropharmacology, 2014, 37, 166-172.	0.7	1
112	Perioperative Atrial Fibrillation and the Long-term Risk of Ischemic Stroke. JAMA - Journal of the American Medical Association, 2014, 312, 616.	7.4	266
113	Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia. Parkinsonism and Related Disorders, 2014, 20, 32-36.	2.2	16
114	Hereditary spastic paraparesis in adults. A clinical and genetic perspective from Tuscany. Clinical Neurology and Neurosurgery, 2014, 120, 14-19.	1.4	22
115	Symptomatic orthostatic tremor associated with Graves' disease. Neurological Sciences, 2014, 35, 929-931.	1.9	10
116	Progression of brain atrophy in the early stages of Parkinson's disease: A longitudinal tensor-based morphometry study in de novo patients without cognitive impairment. Human Brain Mapping, 2014, 35, 3932-3944.	3.6	75
117	Early DEtection of wEaring off in Parkinson disease: The DEEP study. Parkinsonism and Related Disorders, 2014, 20, 204-211.	2.2	121
118	A pilot psychometric study of aberrant salience state in patients with Parkinson's disease and its association with dopamine replacement therapy. Neurological Sciences, 2014, 35, 1603-1605.	1.9	4
119	What is the role for EEG after sleep deprivation in the diagnosis of epilepsy? Issues, controversies, and future directions. Neuroscience and Biobehavioral Reviews, 2014, 47, 533-548.	6.1	15
120	Hearing loss and cognitive decline in older adults: questions and answers. Aging Clinical and Experimental Research, 2014, 26, 567-573.	2.9	58
121	Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Movement Disorders, 2014, 29, 1273-1280.	3.9	200
122	Occurrence of Takotsubo syndrome in a patient with Parkinson's disease after entacapone add-on. Parkinsonism and Related Disorders, 2014, 20, 1313-1314.	2.2	14
123	Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: A case series. Parkinsonism and Related Disorders, 2014, 20, 1290-1292.	2.2	12
124	Development and Psychometric Properties of a Neuropsychological Battery for Mild Cognitive Impairment with Small Vessel Disease: The VMCI-Tuscany Study. Journal of Alzheimer's Disease, 2014, 43, 1313-1323.	2.6	29
125	Localized Calcific Hematoma of the Scalp Presenting as a Nummular-Like Headache. A Case Report. Headache, 2014, 54, 370-372.	3.9	9
126	Novel MTCYB mutation in a young patient with recurrent stroke-like episodes and status epilepticus. American Journal of Medical Genetics, Part A, 2014, 164, 2922-2925.	1.2	6

#	ARTICLE	IF	CITATIONS
127	Recommendations of the Sleep Study Group of the Italian Dementia Research Association (SINDem) on clinical assessment and management of sleep disorders in individuals with mild cognitive impairment and dementia: a clinical review. <i>Neurological Sciences</i> , 2014, 35, 1329-1348.	1.9	25
128	MR Imaging of the Substantia Nigra at 7 T Enables Diagnosis of Parkinson Disease. <i>Radiology</i> , 2014, 271, 831-838.	7.3	114
129	The genetics of ataxia: through the labyrinth of the Minotaur, looking for Ariadne's thread. <i>Journal of Neurology</i> , 2014, 261, 528-541.	3.6	29
130	Cognitive impairment and cardiovascular disease: So near, so far. <i>International Journal of Cardiology</i> , 2014, 175, 21-29.	1.7	51
131	Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 671-672.	2.2	31
132	Caudate dopaminergic denervation and visual hallucinations: Evidence from a 123I-FP-CIT SPECT study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 761-765.	2.2	30
133	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e94661.	2.5	155
134	Myopathic Involvement and Mitochondrial Pathology in Kennedy Disease and in Other Motor Neuron Diseases. <i>Current Molecular Medicine</i> , 2014, 14, 598-602.	1.3	11
135	Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson's disease. <i>Neurological Sciences</i> , 2013, 34, 1751-1758.	1.9	12
136	Affective theory of mind in patients with Parkinson's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2013, 67, 273-276.	1.8	30
137	Diagnosis, assessment and management of delusional jealousy in Parkinson's disease with and without dementia. <i>Neurological Sciences</i> , 2013, 34, 1537-1541.	1.9	14
138	Twinkle mutation in an Italian family with external progressive ophthalmoplegia and parkinsonism: A case report and an update on the state of art. <i>Neuroscience Letters</i> , 2013, 556, 1-4.	2.1	34
139	Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. <i>Therapeutic Advances in Psychopharmacology</i> , 2013, 3, 101-113.	2.7	79
140	Oxidative stress and APO E polymorphisms in Alzheimer's disease and in mild cognitive impairment. <i>Free Radical Research</i> , 2013, 47, 569-576.	3.3	40
141	Cognitive correlates of negative symptoms in behavioral variant frontotemporal dementia: implications for the frontal lobe syndrome. <i>Neurological Sciences</i> , 2013, 34, 1893-1896.	1.9	13
142	Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter study. <i>Movement Disorders</i> , 2013, 28, 1391-1397.	3.9	114
143	How Aware Are Migraineurs of Their Triggers?. <i>Headache</i> , 2013, 53, 834-837.	3.9	23
144	Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 5-15.	3.3	290

#	ARTICLE	IF	CITATIONS
145	The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 124-131.	1.3	26
146	Behavioral and Psychological Symptoms of Dementia: Factor Analysis and Relationship with Cognitive Impairment. <i>European Neurology</i> , 2013, 69, 76-82.	1.4	23
147	fMRI changes in cortical activation during task performance with the unaffected hand partially reverse after ropinirole treatment in de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 265-268.	2.2	14
148	Paroxysmal exertion-induced dystonia secondary to Erdheim-Chester disease. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1105-1106.	1.4	0
149	Nigral involvement and nigrostriatal dysfunction in Huntington's disease: Evidences from an MRI and SPECT study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 800-805.	2.2	13
150	Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: A SPECT follow-up study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 557-559.	2.2	33
151	Triggers in Allodynic and Non-Allodynic Migraineurs. A Clinic Setting Study. <i>Headache</i> , 2013, 53, 152-160.	3.9	25
152	Diagnosis of possible Mild Cognitive Impairment in Parkinson's disease: Validity of the SCOPA-Cog. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1160-1163.	2.2	24
153	Ischemic stroke in patients on oral anticoagulant therapy for a cardioembolic risk factor: always due to cardioembolism?. <i>Neurological Sciences</i> , 2013, 34, 1703-1704.	1.9	2
154	Intra-arterial tissue plasminogen activator and abciximab in patients with acute basilar artery occlusion. <i>Neurological Sciences</i> , 2013, 34, 1871-1873.	1.9	3
155	Vascular Factors and Mitochondrial Dysfunction: a Central Role in the Pathogenesis of Alzheimer's Disease. <i>Current Neurovascular Research</i> , 2013, 10, 76-80.	1.1	26
156	Variant of Rett Syndrome and CDKL5 Gene: Clinical and Autonomic Description of 10 Cases. <i>Neuropediatrics</i> , 2013, 44, 237-238.	0.6	1
157	Corticobasal Syndrome Presenting With Partial Gerstmann's Syndrome and Digit Agnosia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, E70-E70.	1.8	1
158	A Single-Center, Cross-Sectional Prevalence Study of Impulse Control Disorders in Parkinson Disease. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 691-694.	1.4	79
159	From Aberrant Salience to Jumping to Conclusions. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 149-151.	1.4	6
160	Alteration of affective theory of mind in amnesic mild cognitive impairment. <i>Journal of Neuropsychology</i> , 2013, 7, 121-131.	1.4	27
161	Progressive Impairment of Decision-Making in Behavioral-Variant Frontotemporal Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, E20-E21.	1.8	3
162	Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction. <i>European Journal of Neurology</i> , 2013, 20, 480-485.	3.3	52

#	ARTICLE	IF	CITATIONS
163	Expanding the clinical phenotype of <i>DYT5</i> mutations: Is multiple system atrophy a possible one?. Neurology, 2013, 81, 301-302.	1.1	10
164	Reply: Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study. Movement Disorders, 2013, 28, 689-690.	3.9	0
165	Prefrontal cortex, dopamine, and jealousy endophenotype. CNS Spectrums, 2013, 18, 6-14.	1.2	22
166	Levetiracetam-responsive myoclonus in spinocerebellar ataxia type 15. Movement Disorders, 2013, 28, 1465-1465.	3.9	7
167	3-T Magnetic Resonance Angiography in Primary Angiitis of the Central Nervous System. Journal of Computer Assisted Tomography, 2013, 37, 493-498.	0.9	15
168	Mapping Cortical Degeneration in ALS with Magnetization Transfer Ratio and Voxel-Based Morphometry. PLoS ONE, 2013, 8, e68279.	2.5	22
169	Variant of Rett Syndrome and CDKL5 Gene: Clinical and Autonomic Description of 10 Cases. Neuropediatrics, 2012, 43, 037-043.	0.6	27
170	Impairment of Affective Theory of Mind in Corticobasal Degeneration. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, E7-E7.	1.8	5
171	The "Closing-In" Phenomenon in Parkinson's Disease Dementia and Lewy-Body Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, E38-E39.	1.8	10
172	Alexithymia Is Associated With Impulsivity in Newly-Diagnosed, Drug-Naïve Patients With Parkinson's Disease: An Affective Risk Factor for the Development of Impulse-Control Disorders?. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, E36-E37.	1.8	13
173	Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naïve patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 601-606.	1.9	130
174	The Epidemiology and Clinical Manifestations of Dysexecutive Syndrome in Parkinson's Disease. Frontiers in Neurology, 2012, 3, 159.	2.4	31
175	Relationship Between Neuropsychiatric Symptoms and Cognitive Performance in De Novo Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, E22-E23.	1.8	7
176	Impulse control disorders in Parkinson's disease: the role of personality and cognitive status. Journal of Neurology, 2012, 259, 2269-2277.	3.6	42
177	Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines. Movement Disorders, 2012, 27, 1706-1706.	3.9	9
178	Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study. Movement Disorders, 2012, 27, 1679-1682.	3.9	48
179	Essential tremor is a neurodegenerative disease. Journal of Neural Transmission, 2012, 119, 1383-1387.	2.8	44
180	Bilateral Thalamic Infarct Caused by Spontaneous Vertebral Artery Dissection in Pre-eclampsia with HELLP Syndrome: A Previously Unreported Association. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 914.e9-914.e10.	1.6	11

#	ARTICLE	IF	CITATIONS
181	The relationship between cerebral vascular disease and parkinsonism: The VADO study. Parkinsonism and Related Disorders, 2012, 18, 775-780.	2.2	58
182	Orbital and ventromedial prefrontal cortex functioning in Parkinson's disease: Neuropsychological evidence. Brain and Cognition, 2012, 79, 23-33.	1.8	32
183	A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. Expert Opinion on Pharmacotherapy, 2012, 13, 2269-2280.	1.8	25
184	Depressive symptoms in Parkinson's disease. Comprehensive Psychiatry, 2012, 53, 727-731.	3.1	9
185	Affective symptoms and cognitive functions in Parkinson's disease. Journal of the Neurological Sciences, 2012, 317, 97-102.	0.6	52
186	Personality traits in patients with Parkinson's disease: assessment and clinical implications. Journal of Neurology, 2012, 259, 1029-1038.	3.6	74
187	Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale. Neurological Sciences, 2012, 33, 689-694.	1.9	18
188	Iowa gambling task in de novo Parkinson's disease: A comparison between good and poor performers. Movement Disorders, 2012, 27, 330-332.	3.9	6
189	Hypoactivation of the primary sensorimotor cortex in de novo Parkinson's disease. Neuroradiology, 2012, 54, 261-268.	2.2	29
190	Iowa Gambling Task in Parkinson's Disease. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 395-409.	1.3	39
191	Theory of Mind in Parkinson's disease. Behavioural Brain Research, 2011, 219, 342-350.	2.2	72
192	Mild cognitive impairment and cognitive reserve in Parkinson's disease. Parkinsonism and Related Disorders, 2011, 17, 579-586.	2.2	86
193	From Narcissistic Personality Disorder to Frontotemporal Dementia: A Case Report. Behavioural Neurology, 2011, 24, 173-176.	2.1	3
194	Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. PLoS ONE, 2011, 6, e18301.	2.5	84
195	Decision-Making Impairment May Precede Limb Apraxia in Corticobasal Degeneration. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, E29-E29.	1.8	0
196	Impulsivity Is Associated With Decision-Making Deficits in De-Novo Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, E26-E26.	1.8	0
197	Effect of metadoxine on striatal dopamine levels in C57 Black mice. Journal of Pharmacy and Pharmacology, 2011, 45, 476-478.	2.4	10
198	A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica, 2011, 96, 1708-1711.	3.5	122

#	ARTICLE	IF	CITATIONS
199	Event-Based Prospective Memory in Newly Diagnosed, Drug-Naive Parkinson's Disease Patients. Journal of the International Neuropsychological Society, 2011, 17, 1158-1162.	1.8	12
200	Low frequency stimulation of the nucleus tegmenti pedunculo pontini increases cortical metabolism in Parkinsonian patients. European Journal of Neurology, 2011, 18, 842-849.	3.3	32
201	Postpartum Headache Due to Spontaneous Cervical Artery Dissection. Headache, 2011, 51, 809-813.	3.9	17
202	The association between motor subtypes and alexithymia in de novo Parkinson's disease. Journal of Neurology, 2011, 258, 1042-1045.	3.6	30
203	The neuropsychological correlates of pathological lying: evidence from behavioral variant frontotemporal dementia. Journal of Neurology, 2011, 258, 2009-2013.	3.6	14
204	Alzheimer and his disease: a brief history. Neurological Sciences, 2011, 32, 275-279.	1.9	104
205	Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. Movement Disorders, 2011, 26, 464-468.	3.9	139
206	Alexithymia Is Associated with Depression in de novo Parkinson's Disease. Psychotherapy and Psychosomatics, 2011, 80, 251-253.	8.8	28
207	From narcissistic personality disorder to frontotemporal dementia: a case report. Behavioural Neurology, 2011, 24, 173-6.	2.1	3
208	Alexithymia may modulate decision making in patients with de novo Parkinson's disease. Functional Neurology, 2011, 26, 127-31.	1.3	9
209	Out-of-Control Sexual Behavior in an Orbitofrontal Cortex-Damaged Elderly Patient. Journal of Neuropsychiatry and Clinical Neurosciences, 2010, 22, 247.e7-247.e7.	1.8	4
210	Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders. Journal of Neurology, 2010, 257, 276-283.	3.6	38
211	A case of idiopathic low CSF pressure headache presenting as cough headache. Neurological Sciences, 2010, 31, 789-791.	1.9	6
212	Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2010, 9, 969-977.	10.2	377
213	Decision making in de novo Parkinson's disease. Movement Disorders, 2010, 25, 1432-1436.	3.9	56
214	Parkinson's Disease and pathological gambling: Results from a functional MRI study. Movement Disorders, 2010, 25, 2449-2453.	3.9	57
215	Differences in nigrostriatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. European Journal of Neurology, 2010, 17, 626-630.	3.3	75
216	~Airplane headache~™ with aura. Cephalalgia, 2010, 30, 624-625.	3.9	12

#	ARTICLE	IF	CITATIONS
217	Nummular headache dramatically responsive to indomethacin. Cephalalgia, 2010, 30, 1151-1152.	3.9	24
218	Cerebellar Ataxia with Complete Clinical Recovery and Resolution of MRI Lesions Related to Central Pontine Myelinolysis: Case Report and Literature Review. Case Reports in Neurology, 2010, 2, 157-162.	0.7	9
219	A Combination of CSF Tau Ratio and Midsagittal Midbraintopons Atrophy for the Early Diagnosis of Progressive Supranuclear Palsy. Journal of Alzheimer's Disease, 2010, 22, 195-203.	2.6	18
220	Nonmotor symptoms in Parkinson's disease: the dark side of the moon. Future Neurology, 2010, 5, 851-871.	0.5	10
221	The hOGG1 Ser326Cys polymorphism is not associated with sporadic Parkinson's disease. Neuroscience Letters, 2010, 473, 248-251.	2.1	17
222	Levodopa response in dementia with lewy bodies: A 1-year follow-up study. Parkinsonism and Related Disorders, 2010, 16, 522-526.	2.2	45
223	Neuroleptic Malignant Syndrome: Further Lessons From a Case Report. Psychosomatics, 2010, 51, 349-354.	2.5	15
224	Decreased and increased cortical activation coexist in de novo Parkinson's disease. Experimental Neurology, 2010, 224, 299-306.	4.1	30
225	Neuroleptic Malignant Syndrome: Further Lessons From a Case Report. Psychosomatics, 2010, 51, 349-354.	2.5	5
226	Decision-Making Impairment in a Patient With New Concomitant Diagnoses of Parkinson's Disease and HIV. Journal of Neuropsychiatry and Clinical Neurosciences, 2009, 21, 352-353.	1.8	4
227	Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Movement Disorders, 2009, 24, 541-550.	3.9	112
228	Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Movement Disorders, 2009, 24, 1028-1033.	3.9	53
229	Bilateral thalamic glioma presenting with parkinsonism. Movement Disorders, 2009, 24, 2168-2169.	3.9	11
230	SUNA Syndrome With Seasonal Pattern. Headache, 2009, 49, 912-914.	3.9	6
231	“Parkinson-dementia” diseases: A comparison by double tracer SPECT studies. Parkinsonism and Related Disorders, 2009, 15, 762-766.	2.2	25
232	Introduction. Parkinsonism and Related Disorders, 2009, 15, S1.	2.2	2
233	Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S44-S53.	2.2	62
234	Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism and Related Disorders, 2009, 15, S111-S115.	2.2	101

#	ARTICLE	IF	CITATIONS
235	Decision-Making Impairment in a Patient With New Concomitant Diagnoses of Parkinson's Disease and HIV. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009, 21, 352-353.	1.8	0
236	The arginine growth hormone stimulation test in bradykineticâ€rigid parkinsonisms. <i>Movement Disorders</i> , 2008, 23, 190-194.	3.9	11
237	Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study. <i>Movement Disorders</i> , 2008, 23, 2049-2054.	3.9	35
238	PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , 2008, 29, 565-565.	2.5	74
239	â€Indotestâ€™ in Atypical Hemicrania Continua. <i>Cephalalgia</i> , 2008, 28, 300-301.	3.9	18
240	Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype. <i>Neuroscience Letters</i> , 2008, 444, 83-86.	2.1	11
241	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 266-267.	2.2	0
242	The mtDNA A8344G â€MERRFâ€™ mutation is not a common cause of sporadic Parkinson disease in Italian population. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 381-382.	2.2	13
243	Prevalence of Parkinson's disease and other types of parkinsonism in the Aeolian Archipelago, Sicily. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 572-575.	2.2	13
244	The safety of dopamine agonists in the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 111-127.	2.4	9
245	Pain as a Nonmotor Symptom of Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 1191-4.	4.5	208
246	A Whole-Brain Analysis in De Novo Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2008, 29, 674-680.	2.4	67
247	Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. <i>Neurology</i> , 2008, 71, 1796-1803.	1.1	101
248	COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 1.	2.2	85
249	Role of dopamine agonists in Parkinsonâ€™s disease: an update. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1391-1399.	2.8	13
250	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 528-531.	2.2	77
251	Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. <i>Neuroscience Letters</i> , 2007, 422, 228-231.	2.1	30
252	Influences of dopaminergic treatment on motor cortex in Parkinson disease: A MRI/MRS study. <i>Movement Disorders</i> , 2007, 22, 2170-2175.	3.9	32

#	ARTICLE	IF	CITATIONS
253	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. <i>Movement Disorders</i> , 2007, 22, 1623-1629.	3.9	461
254	A case of sarcoidosis presenting as a non-specific intramedullary lesion. <i>European Journal of Neurology</i> , 2007, 14, 346-349.	3.3	13
255	Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. <i>Acta Neurologica Scandinavica</i> , 2007, 116, 37-42.	2.1	82
256	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. <i>Lancet Neurology</i> , The, 2007, 6, 305-313.	10.2	598
257	Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 279-283.	2.2	8
258	Subcutaneous Apomorphine for Neuroleptic Malignant Syndrome. <i>American Journal of Psychiatry</i> , 2006, 163, 1450-1451.	7.2	13
259	Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Societyâ€“European Section. Part I: early (uncomplicated) Parkinson's disease. <i>European Journal of Neurology</i> , 2006, 13, 1170-1185.	3.3	228
260	Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Societyâ€“European Section (MDSâ€“ES). Part II: late (complicated) Parkinson's disease. <i>European Journal of Neurology</i> , 2006, 13, 1186-1202.	3.3	183
261	Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. <i>Journal of Neural Transmission</i> , 2006, 113, 1787-1790.	2.8	20
262	Chromatic pattern-reversal electroretinograms (ChPERGs) are spared in multiple system atrophy compared with Parkinson's disease. <i>Neurological Sciences</i> , 2006, 26, 395-401.	1.9	40
263	Association between amantadine and the onset of dementia in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1375-1379.	3.9	66
264	Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test. <i>Annals of Neurology</i> , 2006, 60, 611-615.	5.3	36
265	Dopamine agonists in the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 81-89.	2.8	28
266	Subcutaneous Apomorphine for Neuroleptic Malignant Syndrome. <i>American Journal of Psychiatry</i> , 2006, 163, 1450.	7.2	6
267	New pharmacologic horizons in the treatment of Parkinson disease. <i>Neurology</i> , 2006, 67, S30-8.	1.1	81
268	Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. <i>European Journal of Human Genetics</i> , 2005, 13, 748-752.	2.8	197
269	Molecular implications of the human glutathione transferase A-4 gene (hGSTA4) polymorphisms in neurodegenerative diseases. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2005, 579, 107-114.	1.0	13
270	Case-control study of multiple system atrophy. <i>Movement Disorders</i> , 2005, 20, 158-163.	3.9	65

#	ARTICLE	IF	CITATIONS
271	REM sleep behaviour disorder in Parkinson's disease: a questionnaire-based study. Neurological Sciences, 2005, 25, 316-321.	1.9	160
272	Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. Neurology, 2005, 65, 1971-1973.	1.1	36
273	The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology, 2005, 64, 1810-1812.	1.1	136
274	A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 388-395.	1.9	178
275	Psychiatric comorbidity in a population of Parkinson's disease patients. European Journal of Neurology, 2004, 11, 315-320.	3.3	173
276	Clozapine for the treatment of levodopa-induced dyskinesias. Lancet Neurology, The, 2004, 3, 268.	10.2	1
277	Validation of the Guidelines for the Diagnosis of Dementia and Alzheimer's Disease of the Italian Neurological Society. Study in 72 Italian neurological centres and 1549 patients. Neurological Sciences, 2004, 25, 289-295.	1.9	15
278	Environmental factors and Parkinson's disease: a case-control study in the Tuscany region of Italy. Parkinsonism and Related Disorders, 2004, 10, 481-485.	2.2	25
279	Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease. Neurological Sciences, 2003, 24, 162-163.	1.9	36
280	Bedtime cabergoline in Parkinson's disease patients with excessive daytime sleepiness induced by dopamine agonists. Neurological Sciences, 2003, 24, 170-171.	1.9	13
281	Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice. Brain Research, 2003, 973, 298-302.	2.2	12
282	Clinical Pharmacokinetics of Cabergoline. Clinical Pharmacokinetics, 2003, 42, 633-645.	3.5	53
283	Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats. Parkinsonism and Related Disorders, 2003, 9, 145-150.	2.2	26
284	Orthostatic Hypotension in De Novo Parkinson Disease. Archives of Neurology, 2003, 60, 1400.	4.5	93
285	ELECTROPHYSIOLOGICAL EVALUATION OF GENITO-SPHINCTERIC DYSFUNCTION IN MULTIPLE SYSTEM ATROPHY. International Journal of Neuroscience, 2003, 113, 1353-1369.	1.6	8
286	Changes in Pattern Electroretinograms to Equiluminant Red-Green and Blue-Yellow Gratings in Patients with Early Parkinson's Disease. Journal of Clinical Neurophysiology, 2003, 20, 375-381.	1.7	70
287	Comparing dopamine agonists in Parkinson's disease. Current Opinion in Neurology, 2003, 16, S13-S19.	3.6	37
288	Dopaminergic Modulation of Visual-Spatial Working Memory in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2003, 15, 55-66.	1.5	105

#	ARTICLE	IF	CITATIONS
289	Treatment of Patients With Tardive Dystonia With Olanzapine. <i>Clinical Neuropharmacology</i> , 2002, 25, 71-74.	0.7	31
290	Comparison of the Unified Parkinson's Disease Rating Scale and the Short Parkinson's Evaluation Scale in Patients With Parkinson's Disease After Levodopa Loading. <i>Clinical Neuropharmacology</i> , 2002, 25, 83-88.	0.7	11
291	Activity-Based Diary for Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2002, 25, 43-50.	0.7	27
292	Motor Response to Apomorphine in Patients With Parkinson's Disease With Long-Duration Response to Levodopa. <i>Clinical Neuropharmacology</i> , 2002, 25, 119-121.	0.7	2
293	Pergolide in the Treatment of Patients With Early and Advanced Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2002, 25, 1-10.	0.7	27
294	Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. <i>Blood</i> , 2002, 100, 2246-2248.	1.4	54
295	Impaired attention modulation of the blink reflex R3 component in Parkinson's disease: a non-task warning paradigm study. <i>International Journal of Psychophysiology</i> , 2002, 44, 83-91.	1.0	3
296	Amantadine in Huntington's disease: open-label video-blinded study. <i>Neurological Sciences</i> , 2002, 23, s83-s84.	1.9	32
297	Cytogenetic alterations in lymphocytes of Alzheimer's disease and Parkinson's disease patients. <i>Neurological Sciences</i> , 2002, 23, s97-s98.	1.9	71
298	Contribution of cerebellum and brainstem in the control of eye movement: evidence from a functional study in a clinical model. <i>Acta Neurologica Scandinavica</i> , 2002, 105, 32-39.	2.1	1
299	Seizures and movement disorders precipitated by drugs. , 2001, , 465-510.		0
300	SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study. <i>Clinical Neuropharmacology</i> , 2001, 24, 221-227.	0.7	97
301	Proton magnetic resonance spectroscopy (¹ H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients. <i>Neurological Sciences</i> , 2001, 22, 69-70.	1.9	86
302	Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients. <i>Neurological Sciences</i> , 2001, 22, 83-84.	1.9	42
303	Epidemiology of multiple system atrophy. <i>Neurological Sciences</i> , 2001, 22, 97-99.	1.9	52
304	Epidemiology of progressive supranuclear palsy. <i>Neurological Sciences</i> , 2001, 22, 101-103.	1.9	29
305	No evidence of association between CAG expansions and essential tremor in a large cohort of Italian patients. <i>Journal of Neural Transmission</i> , 2001, 108, 297-304.	2.8	16
306	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. <i>Movement Disorders</i> , 2001, 16, 197-201.	3.9	111

#	ARTICLE	IF	CITATIONS
307	Intravenous amantadine improves levodopa-induced dyskinesias: An acute double-blind placebo-controlled study. <i>Movement Disorders</i> , 2001, 16, 515-520.	3.9	131
308	Chromosome and oxidative damage biomarkers in lymphocytes of Parkinson's disease patients. <i>International Journal of Hygiene and Environmental Health</i> , 2001, 204, 61-66.	4.3	51
309	Clinical diagnosis of multiple system atrophy: level of agreement between Quinn's criteria and the consensus conference guidelines. <i>Acta Neurologica Scandinavica</i> , 2001, 103, 261-264.	2.1	18
310	Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 71, 685-687.	1.9	35
311	Mexiletine in the Treatment of Torticollis and Generalized Dystonia. <i>Clinical Neuropharmacology</i> , 2000, 23, 186-189.	0.7	41
312	Diurnal Motor Variations to Repeated Doses of Levodopa in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2000, 23, 28-33.	0.7	63
313	Paraneoplastic choreic syndrome during non-Hodgkin's lymphoma. <i>Movement Disorders</i> , 2000, 15, 350-352.	3.9	49
314	Peripheral-type benzodiazepine receptors in human blood cells of patients affected by migraine without aura. <i>Neurochemistry International</i> , 2000, 37, 363-368.	3.8	1
315	Spinocerebellar ataxia type 2 in southern Italy: a clinical and molecular study of 30 families. <i>Journal of Neurology</i> , 1999, 246, 467-471.	3.6	59
316	Acute and chronic effects of clozapine in essential tremor. <i>Movement Disorders</i> , 1999, 14, 468-472.	3.9	69
317	The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. <i>Neuroscience Letters</i> , 1999, 274, 61-65.	2.1	26
318	Pharmacokinetics and Pharmacodynamics of L-DOPA After Acute and 6-Week Tolcapone Administration in Patients with Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1999, 22, 24-29.	0.7	28
319	Prevalence of headache syndromes in panic disorder. <i>International Clinical Psychopharmacology</i> , 1999, 14, 247-251.	1.7	28
320	Flunarizine in Migraine Prophylaxis: Predictive Factors for A Positive Response. <i>Cephalalgia</i> , 1998, 18, 349-352.	3.9	17
321	Evaluation of the Short Parkinson's Evaluation Scale. <i>Clinical Neuropharmacology</i> , 1997, 20, 322-337.	0.7	51
322	Species differences in the role of excitatory amino acids in experimental parkinsonism. <i>Neuroscience and Biobehavioral Reviews</i> , 1997, 21, 401-415.	6.1	47
323	Spontaneous and induced aneuploidy in peripheral blood lymphocytes of patients with Alzheimer's disease. <i>Human Genetics</i> , 1997, 101, 299-305.	3.8	84
324	A case of pelvic floor myoclonic jerk syndrome. <i>Movement Disorders</i> , 1996, 11, 331-333.	3.9	4

#	ARTICLE	IF	CITATIONS
325	Amitriptyline and Dexamethasone Combined Treatment in Drug-Induced Headache. Cephalalgia, 1996, 16, 197-200.	3.9	37
326	Long-term Follow-up after Flunarizine or Nimodipine Discontinuation in Migraine Patients. Cephalalgia, 1996, 16, 337-340.	3.9	22
327	Headache, Panic Disorder and Depression: Comorbidity or a Spectrum?. Neuropsychobiology, 1995, 31, 125-129.	1.9	55
328	White Matter Hyperintensities in Parkinson's Disease. Archives of Neurology, 1995, 52, 191.	4.5	104
329	Myopathic involvement in two cases of Hallervorden-Spatz disease. Brain and Development, 1995, 17, 286-290.	1.1	9
330	Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia. Current Therapeutic Research, 1995, 56, 250-257.	1.2	6
331	Transcranial Doppler Ultrasound in Migraine and Tension-Type Headache After Apomorphine Administration: Double-Blind Crossover Versus Placebo Study. Cephalalgia, 1995, 15, 399-403.	3.9	9
332	Platelet 3H-Imipramine Binding and Sulphotransferase Activity in Primary Headache. Cephalalgia, 1994, 14, 210-214.	3.9	15
333	White Matter MRI Hyperintensities in a Hundred and Twenty-Nine Consecutive Migraine Patients. Cephalalgia, 1994, 14, 342-345.	3.9	75
334	Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study. Movement Disorders, 1994, 9, 431-436.	3.9	80
335	Motor expression of kainic acid seizures is attenuated by dopamine depletion in mice. Brain Research, 1994, 657, 269-274.	2.2	6
336	A neurotropic approach to the treatment of multi-infarct dementia using L-1±-glycerylphosphorylcholine. Current Therapeutic Research, 1992, 52, 741-752.	1.2	9
337	Dextromethorphan and parkinsonism. Lancet, The, 1992, 340, 53.	13.7	49
338	Apomorphine in malignant syndrome due to levodopa withdrawal. Italian Journal of Neurological Sciences, 1992, 13, 169-170.	0.1	16
339	Phenobarbital in the prophylaxis of late posttraumatic seizures. Italian Journal of Neurological Sciences, 1992, 13, 755-760.	0.1	16
340	Platelet peripheral benzodiazepine receptors are decreased in Parkinson's disease. Life Sciences, 1991, 48, 1185-1190.	4.3	17
341	The acute convulsant effect of MPTP is dependent on intracerebral MPP+. Neuroscience Letters, 1991, 124, 22-26.	2.1	6
342	Descriptive Epidemiologic Study of Epilepsy Syndromes in a District of Northwest Tuscany, Italy. Epilepsia, 1991, 32, 294-298.	5.1	40

#	ARTICLE	IF	CITATIONS
343	Naloxone Partly Counteracts Apomorphine Side Effects. Clinical Neuropharmacology, 1991, 14, 442-449.	0.7	14
344	Domperidone-induced acute dystonia and polycystic ovary syndrome. Movement Disorders, 1991, 6, 79-81.	3.9	21
345	Altered Neuroendocrine Regulation of Luteinizing Hormone Secretion in Postmenopausal Women with Parkinson's Disease. Neuroendocrinology, 1991, 53, 549-555.	2.5	7
346	Reduced luteinizing hormone secretion in women with Parkinson's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1990, 2, 225-231.	1.2	11
347	Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1990, 2, 139-147.	1.2	13
348	Possible Involvement of Dopaminergic Mechanisms in the Antimigraine Action of Flunarizine. Cephalalgia, 1990, 10, 3-8.	3.9	22
349	Platelet monoamine oxidase B activity in parkinsonian patients.. Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 854-855.	1.9	22
350	Effect of naloxone on body temperature in postmenopausal women with Parkinson's disease. Life Sciences, 1990, 46, 1241-1247.	4.3	11
351	Platelet monoamine oxidase in dementia of Alzheimer type. Pharmacological Research Communications, 1988, 20, 52.	0.2	1
352	Adrenomyeloneurodystrophy with late cerebral involvement and evidence of a multiple autoimmune disorder. Journal of Inherited Metabolic Disease, 1988, 11, 169-172.	3.6	11
353	Flunarizine increases PRL secretion in normal and in migraineous women. Journal of Neural Transmission, 1988, 74, 43-53.	2.8	10
354	Oral Thyrotropin-Releasing Hormone Treatment in Inherited Ataxias. Clinical Neuropharmacology, 1988, 11, 520-528.	0.7	10
355	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol or acetaldehyde. Life Sciences, 1987, 40, 827-832.	4.3	41
356	Properties of 3H-MPTP binding sites in human blood platelets. Life Sciences, 1986, 39, 1885-1891.	4.3	3
357	Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: Binding and biochemical studies. Brain Research, 1986, 378, 320-324.	2.2	12
358	Prolactin Secretion in Epileptic Subjects Treated with Phenobarbital: Sex Differences and Circadian Periodicity. Epilepsia, 1986, 27, 142-148.	5.1	14
359	Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients. Journal of Neural Transmission, 1985, 64, 105-111.	2.8	20
360	Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluorenone: Two case reports. Italian Journal of Neurological Sciences, 1983, 4, 207-210.	0.1	6

#	ARTICLE	IF	CITATIONS
361	Phenobarbital prophylaxis of post traumatic epilepsy. Neurological Sciences, 1979, 1, 223-230.	1.9	0
362	Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease-in Parkinson's disease- Cognition (SCOPA-Cog). Functional Neurology, 0, , .	1.3	3